Akingbola Adewunmi, Adegbesan Abiodun, Adegoke Kolade, Chuku Joel, Ojo Olajide, Mariaria Petra, Alao Uthman, Salami Raolat Adenike, Oladunjoye Michael
Department of Public Health and Primary Care, University of Cambridge, Old Schools, Trinity Lane, Cambridgeshire, Cambridge CB2 1TN, UK.
African Cancer Institute, Department of Global Health, Stellenbosch University, Cape Town, South Africa.
Glob Health Epidemiol Genom. 2025 Apr 21;2025:1015031. doi: 10.1155/ghe3/1015031. eCollection 2025.
Chandipura virus (CHPV) is an emerging rhabdovirus primarily affecting pediatric populations in India, causing acute encephalitis syndrome (AES) with high mortality rates. First identified in 1965, CHPV has resurfaced in several outbreaks, the most recent being in 2024, with significant public health implications. The virus is transmitted primarily by sandflies, particularly spp., and has been associated with a rapid progression of symptoms, leading to severe neurological damage and death. Despite advances in diagnostic techniques, no specific antiviral treatment or licensed vaccine currently exists. This manuscript reviews the latest findings on CHPV, focusing on diagnostic advancements, treatment strategies, and public health responses. Reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) have emerged as vital tools for rapid and accurate diagnosis, enabling the identification of CHPV in clinical and environmental samples. Antiviral therapies, such as ribavirin and favipiravir, have shown promise in vitro and preclinical models, but human trials are lacking. Additionally, the virus's unique epidemiology, including its reliance on sandfly transmission, complicates control efforts, particularly in resource-limited settings. The 2024 outbreak, with a case fatality ratio of over 30%, highlights the urgent need for improved surveillance, vector control measures, and public health interventions to curb the spread of CHPV. Despite considerable progress in diagnostics and experimental treatments, significant challenges remain in controlling CHPV outbreaks. The lack of specific antiviral therapies and vaccines continues to hinder effective management. Strengthened vector control strategies, advanced diagnostic infrastructure, and ongoing research into antiviral development are essential for mitigating the impact of CHPV in affected regions. International collaboration and sustained public health efforts will be crucial in preventing future outbreaks and reducing the disease burden.
钱迪普拉病毒(CHPV)是一种新出现的弹状病毒,主要影响印度的儿童群体,可导致急性脑炎综合征(AES),死亡率很高。CHPV于1965年首次被发现,在几次疫情中再次出现,最近一次是在2024年,具有重大的公共卫生影响。该病毒主要通过白蛉传播,特别是 属的白蛉,并且与症状的快速进展有关,可导致严重的神经损伤和死亡。尽管诊断技术有所进步,但目前尚无特异性抗病毒治疗方法或获得许可的疫苗。 本手稿综述了关于CHPV的最新研究结果,重点关注诊断进展、治疗策略和公共卫生应对措施。逆转录聚合酶链反应(RT-PCR)和酶联免疫吸附测定(ELISA)已成为快速准确诊断的重要工具,能够在临床和环境样本中识别CHPV。抗病毒疗法,如利巴韦林和法匹拉韦,在体外和临床前模型中已显示出前景,但缺乏人体试验。此外,该病毒独特的流行病学,包括其对白蛉传播的依赖,使防控工作复杂化,特别是在资源有限的环境中。2024年的疫情,病死率超过30%,凸显了迫切需要加强监测、病媒控制措施和公共卫生干预措施,以遏制CHPV的传播。 尽管在诊断和实验性治疗方面取得了相当大的进展,但在控制CHPV疫情方面仍存在重大挑战。缺乏特异性抗病毒疗法和疫苗继续阻碍有效管理。加强病媒控制策略、先进的诊断基础设施以及对抗病毒药物研发的持续研究对于减轻CHPV在受影响地区的影响至关重要。国际合作和持续的公共卫生努力对于预防未来疫情和减轻疾病负担至关重要。